Valuation: Moderna, Inc.

Market Cap 55.45B 47.52B 44.46B 40.64B 76.7B 5,309B 77.51B 526B 205B 2,666B 208B 204B 8,821B P/E 2026 *
-16.2x
P/E 2027 * -28.5x
Enterprise Value 51.8B 44.39B 41.53B 37.97B 71.65B 4,960B 72.41B 491B 191B 2,491B 194B 190B 8,241B EV / Sales 2026 *
24.6x
EV / Sales 2027 * 21.7x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day-4.38%
1 week+114.74%
Current month+150.44%
1 month+103.45%
3 months+193.24%
6 months+198.68%
Current year+353.08%
1 week 53.94
Extreme 53.94
143.2
1 month 47.58
Extreme 47.58
143.2
Current year 25.38
Extreme 25.385
143.2
1 year 20.18
Extreme 20.18
143.2
3 years 20.18
Extreme 20.18
155.3
5 years 20.18
Extreme 20.18
390.25
10 years 14.22
Extreme 14.218
430.05
Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 63 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Change 5-day change 1-year change 3-year change Capi.($)
-4.38%+114.74% - - 57.94B
-0.66%+2.80%+40.55%-0.33% 83.28B
-4.30%+115.47%+412.13%+23.29% 57.94B
+3.18%+10.57%-19.36%-33.76% 57.77B
+1.42%+1.61%-0.67%+34.08% 51.75B
-0.77%+2.14%+11.51%+170.00% 49.35B
+0.62%+4.29%+56.57%-16.88% 32.03B
+0.13%+3.63%+50.49%+99.25% 25.91B
+1.51%+4.40%+0.95%+198.52% 22.74B
-1.74%-1.27%+55.54%+107.91% 16.87B
Average -0.51%+18.56%+67.52%+64.68% 44.18B
Weighted average by Cap. -0.69%+22.64%+77.33%+44.99%

Financials

2026 *2027 *
Net sales 2.11B 1.81B 1.69B 1.54B 2.91B 202B 2.94B 19.98B 7.77B 101B 7.91B 7.74B 335B 2.46B 2.11B 1.97B 1.8B 3.4B 235B 3.44B 23.31B 9.06B 118B 9.23B 9.03B 391B
Net income -3.38B -2.9B -2.71B -2.48B -4.67B -324B -4.72B -32.06B -12.46B -162B -12.69B -12.41B -538B -1.9B -1.62B -1.52B -1.39B -2.62B -181B -2.65B -17.98B -6.99B -91.13B -7.12B -6.96B -302B
Net Debt -3.65B -3.13B -2.93B -2.67B -5.05B -349B -5.1B -34.62B -13.46B -175B -13.7B -13.4B -581B -2.19B -1.88B -1.76B -1.61B -3.03B -210B -3.07B -20.81B -8.09B -105B -8.24B -8.06B -349B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
26-08-24 €119.98 -5.54% 2,500
26-08-21 €127.02 +10.68% 4,591
26-08-20 €114.76 -14.09% 758
26-08-19 €133.58 +142.21% 1,672
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
23
Last Close Price
138.89USD
Average target price
95.67USD
Spread / Average Target
-31.12%

Quarterly revenue - Rate of surprise